

SESSION 4: MORE NEW DEVELOPMENTS IN THE TREATMENT OF TBADS, THORACIC AORTIC DISEASE AND THORACOABDOMINAL ANEURYSMS (TAAAS)

When Should Hybrid Treatment (Endograft Proximal + Open Distal) Be the Preferred Treatment for TAAA Repair: Advantages and T<u>echnical Tips</u>

> Gilbert R. Upchurch, Jr., MD Edward M. Copeland, III, MD and Ann & Ira Horowitz Chair of Surgery



Original Hybrid Repair for TAAA: Open Debranching then EVAR/TEVAR Hybrid Repair of Aortic Aneurysms Involving the Visceral and Renal Vessels

Background: We cought to analyme our experience with hybrid hadment of bacits anaurymes moving the real and viscoel a streter. Methods: We cought could be an experience of 36 consoluble patients and underest positions, conjugate and position of 26 consoluble patients and the consolution and the streter of the streter of 26 consoluble patient comparison and positions and patient patient annual were models. Observational and comparison and positions and positions and positions and positions comparison and positions and positions and positions and positions comparison and positions and positions and positions and positions comparison and positions and positions and positions and positions and analyzes and positions and positions and positions and positions and analyzes and positions and positions and positions and positions and and positions and and positions and positions and positions (25%). There is an experiment of the positions and positions and positions (25%). There is an experiment of the positions and a positions and positions and

Ann Vasc Sura 2010: 24: 219-224







- Left subclavian artery revascularization, if planned coverage
- Endograft from In artery level
- Initially limited coverage Distal type 1 B endoleak expected
- Lumbar drain for 24-48 hours standard



<section-header> Staged Distal Open Repair Aorta and endograft are transected Dissection septum is divided to allow endograft expansion Tapered aortic wall + endograft sewn directly to graft Partial cardiopulmonary bypass, perfusion of mesenterics and renals used











Combined Mid-Term Outcomes –						
Stages 1 and 2						
TEVAR.	(N = 19), No. (%)	Open TAAA repair	(N = 19), No. (%)			
Death	0 (0)	Death	0 (0)			
Stroke/paraplegia	0 (0)	Stroke/paraplegia Acute kidney injury	1 (5.2)			
-			5 (26.3)			
Acute kidney injury	1 (5.2)	(Serum creatinine				
Type I endoleak	2 (10.5)	>2 mg/dL)				
		Chronic renal failure	0 (0)			
Type II endoleak	1 (5.2)					
3 patients with baseline renal insufficiency with pre op GFR < 60 returned to their pre op renal functions. All with S Cr < 2mg/dl						





Risk-adjusted Mortality Outcomes					
Group	HR	95% CI	P-value		
Open:FEVAR	3.59	1.41-9.15	0.01		
Open:FEVAR	2.69	1.24-5.81	0.01		
Open:Hybrid	2.43	1.09-5.44	0.03		
	Copen:FEVAR Open:FEVAR Open:Hybrid	Group HR Open:FEVAR 3.59 Open:FEVAR 2.69 Open:Hybrid 2.43	GroupHR95% ClOpen:FEVAR3.591.41-9.15Open:FEVAR2.691.24-5.81Open:Hybrid2.431.09-5.44		



Summary

• FEVAR and Hybrid vs Open:

- -Similar or better outcomes compared to Open
- 1-year survival (86%) vs Open (69%) --Survival advantage lost over time
- 5-year survival highest for hybrid (60%)

Conclusion

Greater adoption of FEVAR as 1st-line therapy for complex TAAA
 disease
 If anatomically suitable

Ultimately, all 3 strategies are complementary and each has a role